44 results about "Attention deficits" patented technology

The invention relates to the field of medical image analysis and neuropsychiatric disease diagnosis, and particularly discloses a brain network typing diagnosis system and method for attention deficit hyperactivity disorder. Comprising a data acquisition and preprocessing module, a topological feature extraction module, a supervised manifold learning module, a network reconstruction and diagnosis module, a parameter optimization module and a result verification module, continuous homology analysis is performed on a brain region function connection matrix based on an algebraic topology theory, and a brain region topological feature matrix is generated; utilizing supervised manifold learning to map the brain region topological feature matrix to a Riemannian manifold, and calculating a brain region importance weight map based on ADHD phenotypic features as supervised signals; according to the method, the brain network is subjected to subtype specific reconstruction through the curvature flow theory of Riemannian geometry, the topological difference between different subtypes is calculated, accurate typing diagnosis of ADHD is achieved, and the diagnosis accuracy is improved by 15%-20%.

The disclosure relates to, in part, a method of diagnosing whether a patient is afflicted with attention-deficit / hyperactivity disorder (ADHD) and / or selecting ADHD treatment for a patient afflicted with ADHD and / or monitoring response of ADHD symptoms in patient to an ADHD treatment.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

1. The name of the design product: eye movement cognitive and attention assessment training instrument. 2. The use of the design product: for attention deficit groups such as hyperactivity and autism. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The present invention relates to attention training systems and methods, particularly for treating individuals with Attention-Deficit / Hyperactivity Disorder (ADHD). Specifically, the present invention is related to employing biofeedback and virtual reality technologies to enhance gaze control and attention measures. The claimed invention represents a system and method for attention training that improve the relevant technological field by providing and utilizing a highly informative real-time biofeedback reliably representing the user's ability to sustain attention.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for preventing or treating chemobrain, e.g., inhibiting or mitigating one or more symptoms of chemobrain, e.g., feeling of mental fogginess, deficit in attention, disorganized behavior or thinking, confusion, impaired concentration, difficulty finding the right word, difficulty learning new skills, difficulty multitasking, memory impairment (e.g., short-term memory problems, long-term memory problems, impaired verbal memory, impaired visual memory), and / or fatigue.

The present invention relates to the treatment of an executive function disorder, such as attention deficit hyperactivity disorder (ADHD) and / or autism with both lacosamide and oxcarbazepine.

This application relates to a method, apparatus, and device for screening the risk of reading and attention deficit disorder in children. The method includes acquiring multi-channel raw brain blood oxygenation signals under task-induced conditions using a specific layout fNIRS array integrated into a wearable headband, based on a rapid naming cognitive paradigm. Based on the raw brain blood oxygenation signals, a fusion feature vector representing the reading and attention networks is generated by calculating temporal waveform features and frontotemporal functional connectivity strength. The multi-dimensional fusion feature vector is then processed and analyzed using a Transformer classification model to generate classification results indicating the risk level of reading disorders and comorbid ADHD. This application achieves portable and rapid brain function signal acquisition by integrating a targeted fNIRS array with a standardized cognitive paradigm. By fusing temporal dynamics and brain network connectivity features, a multi-dimensional neural representation is constructed. Finally, a lightweight Transformer model is used to output the risk level of reading disorders and comorbid ADHD end-to-end, achieving high-precision automated assisted screening.

The present invention relates to a system and method for real-time screening of Attention Deficit Hyperactivity Disorder using electroencephalographic signals processed through a GPU-accelerated time-frequency inference architecture. The invention enables continuous acquisition of multi-channel electroencephalographic data, adaptive preprocessing for artifact suppression and signal stabilization, and parallel execution of time-frequency transformations to extract neurologically relevant features in real time. Extracted features are analyzed using an inference process configured to identify neurological patterns associated with Attention Deficit Hyperactivity Disorder, while continuous validation of signal quality and temporal consistency ensures diagnostic reliability. The system dynamically adapts analytical parameters based on evolving signal characteristics and regulates computational workload to achieve energy-efficient operation during prolonged monitoring. The invention provides a technically integrated, machine-implemented screening solution capable of delivering reliable, real-time neurological assessment suitable for clinical environments.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

The invention relates to a pellet as well as a preparation method and application thereof. The pellet has a treatment effect on attention deficit and attention disorder of children. The invention also provides a tablet containing the pellet, the tablet comprises active pharmaceutical ingredients and pharmaceutically acceptable auxiliary materials, and the active pharmaceutical ingredients exist in the core pellet. The pellet and the tablet containing the pellet have a good release characteristic.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Kits and diagnostic apparatus include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

The application discloses a game adjusting method and device and a storage medium, and relates to the technical field of games, and can improve the exercise efficiency of attention deficit hyperactivity disorder.

The invention discloses a children attention deficit early intelligent screening system based on multi-modal behavior feature fusion. The system comprises a data acquisition module, a data processing module and a data classification judgment module. The data acquisition module is used for acquiring handwriting data, action feature data and facial expression feature data of a child; the data processing module is used for performing space-time alignment and feature level fusion on the acquired handwriting data, action feature data and facial expression feature data to obtain processed data; and the data classification and judgment module is used for carrying out classification and judgment on the processed data to obtain a screening result and finish early intelligent screening of the attention deficits of children. According to the invention, the Microsoft Surface touch device and the external camera are used for collecting the bottom data in the drawing process of children in real time, and computer vision and a machine learning algorithm are combined, so that the attention defect screening function is realized.

The present technology relates to sensory apparatuses that are useful for individuals who need assistance with neurodevelopmental conditions such as autism spectrum disorder (ASD), sensory processing disorder (SPD), attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). Such apparatuses can include a top cover connected to or integral with a top base plate, and a bottom cover connected to or integral with a bottom base plate, about which projections or wings having different visual or tactile properties, such as different textures, are rotatably attached. The present technology is also directed to systems and methods for the management of a neurodevelopmental condition.

The present invention provides for an oral solution that includes atomoxetine, or pharmaceutically acceptable salt thereof, methods of manufacturing the oral solution, and methods of treating attention deficit hyperactivity disorder (ADHD) in a human subject that include orally administering the oral solution to a human subject in need thereof.

The invention relates to a multifunctional medicine release composition as well as a preparation method and application thereof. The multifunctional medicine release composition has a treatment effect on attention deficit and attention disorder of children. The invention also provides a dispersible sustained-release multi-unit pellet system which comprises an active pharmaceutical ingredient and pharmaceutically acceptable auxiliary materials, and the active pharmaceutical ingredient exists in the core pellet. The invention also relates to a method for preparing the sustained-release multi-unit pellet system by adopting a multi-seal coating technology. The dispersible slow-release multi-unit pellet system disclosed by the invention has a good release characteristic.

The invention relates to the technical field of screening and application of probiotics, in particular to bifidobacterium lactis HC2786 for reducing and removing harm of heavy metal in a body and application of the bifidobacterium lactis HC2786. The bifidobacterium anaticum subsp. Lactis HC2786 is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 20222008, and the preservation date is December 23, 2022, the preservation number is CCTCC NO: M 20222008, the preservation number is CCTCC NO: M 20222008, and the preservation number is CCTCC NO: M 20222008. The strain has a relatively strong adsorption effect on heavy metals such as mercury, silver, cadmium and chromium, is not easy to desorb, can reduce the accumulation level of various heavy metals in a central nervous system, alleviates the toxic action of the heavy metals on the nervous system, effectively improves hyperactivity, anxiety and dysphoria, spatial memory disorder, attention deficit and other hyperactivity disorder related neurological behavior abnormalities, and has a good application prospect. The method has great application value.

The invention involves novel, oral solutions of bitter drugs using Vitamin E TPGS as a masking agent and methods of using the same (e.g., for treating attention deficit / hyperactivity disorder (ADHD)). Atomoxetine (e.g., Atomoxetine HCl) is an example of a bitter drug whose bitterness can be masked by the presence of Vitamin E TPGS alone or in combination with additional ingredients.

The present invention relates to the prophylactic and / or therapeutic treatment of a disease selected from the group consisting of long-term COVID disease, myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) disease, fibromyalgia, dementia, neoplastic disease, autoimmune disease, schizophrenia, epileptic seizure disease, excessive inflammatory disease, chronic inflammatory bowel disease, rheumatic disease, obesity, and the like. Hyperuricemia, diabetes (IDDM / NIDDM), acute viral diseases, amyotrophic lateral sclerosis (ALS), bronchial asthma, atopic allergic disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, autoimmune diseases / antibody-related diseases, bipolar affective disorders, celiac disease (CD), chronic obstructive pulmonary disease (COPD), and the like. Chronic inflammatory bowel disease (CED) (i.e. Crohn's disease, ulcerative colitis), cystic fibrosis / cystic fibrosis, depression, endometriosis, polycystic ovarian syndrome, eating disorders, anxiety disorders, addiction disorders, frontotemporal dementia (Pickk's disease), Graves's disease (GD), generalized cardiovascular diseases, Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosis (MS), and the like. Muscular dystrophy, neurodermatitis, peripheral arterial occlusion disease (PAOD), pneumonia, generalized post-vaccination syndrome and vaccine damage, post-viral infection syndrome, psoriasis, pulmonary arterial hypertension, restless leg syndrome, restrictive pulmonary disease, rheumatoid arthritis (RA), division affective disorder, sepsis, sicca syndrome (SS), scleroderma, and the like. Systemic lupus erythematosus (SLE) and unsatisfactory fertility desires, using an active agent having a nicotinic acetylcholinergic agonist and / or an active agent having a muscarinic acetylcholinergic agonist and / or a muscarinic acetylcholinergic antagonist. This provides a very effective prophylactic and / or therapeutic treatment for these diseases. This prevention or treatment is also readily tolerable, cost effective and easy to apply.

The present disclosure provides pharmaceutical compositions and dosage forms including viloxazine, or a pharmaceutically acceptable salt thereof, processes for the preparation thereof, and their use in the treatment of central nervous system disorders, including Attention-Deficit Hyperactivity Disorder (ADHD).

The present invention relates a method of treating attention-deficit / hyperactivity disorder (ADHD), wherein the patient suffers from mood disorders and / or anxiety. More specifically, the present invention is directed to a method of using a carbamate compound alone or in combination with other medications, for the treatment of ADHD.

An orally disintegrating pharmaceutical tablet comprising: between 0.1 and 21 wt % of cariprazine or its pharmaceutically acceptable salts, between 0.1 and 15 wt % of a disintegrant, between 0.1 and 5 wt % of colloidal silicon dioxide, between 0.1 and 10 wt % of a taste masking agent, between 0.1 and 5 wt % of a lubricant, and up to 100 wt % of a diluent, the percentage being expressed with regard to the total weight of the pharmaceutical tablet. Said composition for use in the treatment and / or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

The present application relates to the field of detection reagents for neurodevelopmental disorders, and in particular to the application of SCN1A in the preparation of a kit for detecting neurodevelopmental disorders, especially the application of specific multiple mutation sites of the gene. These mutation sites include single nucleotide deletion mutations of chr2:165984651, chr2:165984876 and chr2:165984932, which are associated with attention deficit hyperactivity disorder. The kit provided by the present application combines targeted cleavage and fluorescent PCR amplification technology to improve the detection sensitivity of multiple mutation sites of the SCN1A gene. The kit provided by the present application covers multiple SCN1A gene mutation sites, enhances the comprehensiveness of detection, and recognizes complex mutation individuals through threshold effect, thereby improving the sensitivity and specificity of detection.

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and / or improving health, nutrition, and / or another condition of a subject, and / or cognitive, learning, and / or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and / or hypertension. A kit, method, and other associated technology are also provided.